Emeritus Professor Herbie Newell
- Email: email@example.com
- Telephone: +44 (0) 191 208 4300
- Address: NICR Paul O’Gorman Building,
David (Herbie) Newell is Emeritus Professor of Cancer Therapeutics at Newcastle University, England, UK. He was Director of Translational Research at Cancer Research UK from 2006 to 2009, and interim Executive Director of Clinical and Translational Research in 2007/8. He was the founding Scientific Director of the Northern Institute for Cancer Research at Newcastle University, and is Past-Chairman of the British Association for Cancer Research and of the Laboratory Research Division of the European Organisation for Research and Treatment of Cancer. Professor Newell was involved in the development of the registered cytotoxic agents carboplatin (Paraplatin®) and ralitrexed (Tomudex®), and until his retirement in 2016 was working on the discovery and development of molecularly-targeted anticancer drugs and associated predictive and pharmacological biomarkers.
Professor Newell was the lead pharmacologist on the team that discovered the first-in-class PARP inhibitor rucaparib (Rubraca®), for which the team were awarded the inaugural Cancer Research UK Translational Research Team prize. Rucaparib was given “Breakthrough Therapy” status by the US FDA in April 2015 for the treatment of hereditary ovarian cancer, the only PARP inhibitor to have been accorded this designation, and was licensed by the US FDA in December 2016. His specific drug discovery research interests include the identification of enzyme and protein-protein interaction inhibitors, using both structural biology and computational chemistry, and their evaluation in pre-clinical tumour models. Imaging techniques where Professor Newell has research interests include both pre-clinical and clinical Positron Emission Tomography (PET) and Nuclear Magnetic Resonance (NMR) spectroscopy and imaging. He is an author of over 230 scientific articles and was Editor-in-Chief of the journal Cancer Chemotherapy and Pharmacology until 2016. In addition to his academic work, Professor Newell has consulted extensively for both pharmaceutical and biotechnology companies, and speaks widely at public meetings on behalf of Cancer Research UK.
Until 2016, Professor Newell chaired the Medical Research Council Development Pathway Funding Scheme and Confidence-in-Concept Committees, and the Cancer Research Technology Pioneer Fund Advisory Board. He has served on numerous international translational cancer research review panels, most recently in France, Germany, the Netherlands and Malaysia. In 2011, Professor Newell was elected to the UK Academy of Medical Sciences.
Areas of expertise
- Cancer pharmacology
- Drug discovery
- Coxon C, Anscombe E, Harnor S, Martin M, Carbain B, Golding B, Hardcastle I, Harlow L, Korolchuk S, Matheson C, Newell D, Noble M, Sivaprakasam M, Tudhope SJ, Turner D, Wang L, Wedge SR, Wong C, Griffin R, Endicott J, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 2017, 60, 1746-1767.
- Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Molecular Cancer Therapeutics 2017, 16(6), 1010-1020.
- Chen L, Pastorino F, Berry P, Bonner J, Wood K, Veal G, Ponzoni M, Lunec J, Newell DR, Tweddle DA. In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma. In: AACR Annual Meeting 2017. 2017, Washington, DC: American Association for Cancer Research.
- Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 2017, Epub ahead of print.
- Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget 2017, 8(69), 113418-113430.
- Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget 2017, 8, 19089-19124.
- Lebraud H, Noble R, Phillips N, Hearn K, Castro J, Zhao Y, Newell DR, Lunec J, Wedge S, Heightman TD. A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition. Bioconjugate Chemistry 2018, 29(6), 2100-2106.